Home > Cardiology > ESC 2021 > Analysis of VOYAGER PAD shows similar treatment benefit in diabetic patients

Analysis of VOYAGER PAD shows similar treatment benefit in diabetic patients

Presented By
Prof. Cecilia Low Wang, University of Colorado, USA
Conference
ESC 2021
Trial
VOYAGER PAD
A pre-specified analysis of the VOYAGER PAD study showed that diabetic patients with symptomatic peripheral artery disease (PAD) who had just undergone peripheral artery revascularisation have a similar treatment benefit from low-dose rivaroxaban compared with non-diabetics. However, both their rate of treatment discontinuation and their risk of TIMI major bleeding are higher than in non-diabetic patients. The VOYAGER PAD (NCT02504216) study presented a groundbreaking advance for PAD patients who had just undergone peripheral artery revascularisation, who previously had no evidence-based treatment available. In this study, including almost 6,600 patients, the combined antithrombotic regimen of rivaroxaban plus aspirin was safe and effective for reducing ischaemic events in this patient population with an absolute risk reduction of 2.6%. With their pre-specified ana...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on